Evommune, Inc. $EVMN Stock: Andera Partners Decreases Stake

Key Points

• Andera Partners cut its Evommune stake by 93% in the third quarter, selling 1.29 million shares and retaining 97,362 shares worth approximately $804,000.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $30.80, although several firms recently lowered their targets.
• Evommune shares opened at $5.17, near their 52-week low of $5.09, while the company reported a quarterly loss of $0.89 per share, missing estimates by $0.21.

Andera Partners lessened its position in Evommune, Inc. (NYSE:EVMN - Free Report) by 93.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 97,362 shares of the company's stock after selling 1,294,628 shares during the quarter. Evommune makes up about 0.5% of Andera Partners' portfolio, making the stock its 6th biggest position. Andera Partners owned about 0.27% of Evommune worth $804,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Strs Ohio bought a new stake in shares of Evommune in the first quarter worth $41,000. The Manufacturers Life Insurance Company grew its position in Evommune by 25.3% in the first quarter. The Manufacturers Life Insurance Company now owns 12,812 shares of the company's stock valued at $295,000 after purchasing an additional 2,587 shares in the last quarter. Velan Capital Investment Management LP increased its stake in Evommune by 1.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company's stock valued at $5,997,000 after buying an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Evommune in the 1st quarter valued at $508,000. Finally, Bank of America Corp DE increased its stake in Evommune by 928.3% in the 1st quarter. Bank of America Corp DE now owns 30,201 shares of the company's stock valued at $694,000 after buying an additional 27,264 shares during the last quarter.

Analyst Upgrades and Downgrades

EVMN has been the topic of several analyst reports. Stifel Nicolaus set a $30.00 price target on shares of Evommune in a research report on Wednesday, September 9th. Leerink Partners decreased their price objective on Evommune from $28.00 to $22.00 and set an "outperform" rating for the company in a report on Wednesday, September 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Evommune in a research report on Friday, September 18th. Weiss Ratings downgraded Evommune from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, September 11th. Finally, Morgan Stanley dropped their target price on Evommune from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Evommune presently has an average rating of "Moderate Buy" and a consensus target price of $30.80.

Evommune Price Performance

EVMN stock opened at $5.17 on Friday. Evommune, Inc. has a 1 year low of $5.09 and a 1 year high of $33.20. The stock has a market cap of $187.74 million and a price-to-earnings ratio of -0.47. The company has a 50 day simple moving average of $10.45 and a 200 day simple moving average of $16.57.

Evommune (NYSE:EVMN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.21). On average, equities research analysts anticipate that Evommune, Inc. will post -3.29 EPS for the current fiscal year.

Evommune Company Profile

Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company's research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.